KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Extended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial.

Waldemar A Carlo, Eric C Eichenwald, Benjamin A Carper, Edward F Bell, Martin Keszler, Ravi M Patel, Pablo J Sánchez, Ronald N Goldberg, Carl T D'Angio, Krisa P Van Meurs, Anna Maria Hibbs, Namasivayam Ambalavanan, Shirley S Cosby, Nancy S Newman, Betty R Vohr, Michele C Walsh, Abhik Das, Robin K Ohls, Janell Fuller, Matthew A Rysavy, Sarvin Ghavam, Luc P Brion, Karen M Puopolo, Ryan Moore, Michelle L Baack, Tarah T Colaizy, Mariana Baserga, Ahmed F Osman, Stephanie L Merhar, Brenda B Poindexter, Sara B DeMauro, Vasanth Kumar, C Michael Cotten, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network

JAMA 333(24) 2154-2163

PMID40294395
PMCIDPMC12038711
DOI10.1001/jama.2025.5791
发表日期2025-04-28
入排依据:未发现恶性肿瘤人群证据。
已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure.:AI 判定为 flow diagram。
摘要

摘要

IMPORTANCE: Hospitalization of moderately preterm infants may be prolonged while waiting for apnea of prematurity to resolve after discontinuing caffeine. OBJECTIVE: To evaluate whether extending caffeine treatment reduces the duration of hospitalization. DESIGN, SETTING, AND PARTICIPANTS: From February 2019 to December 2022, this randomized clinical trial in 29 US hospitals enrolled infants born at 29 to 33 weeks' gestation who at 33 to 35 weeks' postmenstrual age were receiving caffeine treatment with plans to discontinue it plus receiving full feeds (≥120 mL/kg/d). Follow-up was completed on March 20, 2023. INTERVENTIONS: Infants were randomized to oral caffeine citrate (10 mg/kg/d) or placebo until 28 days after discharge. MAIN OUTCOMES AND MEASURES: The primary outcome was days to discharge after randomization. Secondary outcomes included days to physiological maturity (apnea free for 5 consecutive days, receiving full oral feeds, and out of the incubator for at least 48 hours), postmenstrual age at discharge, all-cause hospital readmissions, all-cause sick and emergency department visits, safety outcomes, and death. RESULTS: A total of 827 infants (median gestational age, 31 weeks; 414 female [51%]) were randomized (416, caffeine; 411, placebo) out of the 878 planned before reaching the prespecified futility threshold. Days of hospitalization after randomization did not differ between groups (18.0 days [IQR, 10 to 30 days] for caffeine vs 16.5 [IQR, 10 to 27 days] for placebo; adjusted median difference, 0 days [95% CI, -1.7 to 1.7 days]), nor did days to physiological maturity differ (14.0 vs 15.0 days, adjusted median difference, -1 day [95% CI, -2.4 to 0.4 days]). Infants receiving caffeine were apnea free sooner (6.0 vs 10.0 days; adjusted median difference, -2.7 days [95% CI, -3.4 to -2.0 days ]) but had similar days to full oral feeding (7.5 vs 6.0 days, adjusted median difference, 0 days [95% CI, -0.1 to 0.1]). Rates of readmissions and sick visits did not differ between groups. There was no statistically significant difference in adverse events between the 2 groups. CONCLUSIONS AND RELEVANCE: In moderately preterm infants, continuation of caffeine treatment compared with placebo did not shorten hospitalization. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03340727.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure.Figure.. Flow of Patients in the Moderately Preterm Infants Discharged With Caffeine at Home for Apnea (MoCHA) Trial a Including oxygen, nasal cannula, continuous positive pressure ventilation, and/or mechanical ventilation. b Excluding atrial septal defect, ventricular septal defect, or patent ductus arteriosus. c Reasons for not randomizing eligible infants were selected from a predetermined set of likely reasons. Other reasons were uncategorized free text. PMA indicates postmenstrual age.
非 KM Figure